SC
RVNC

Steven Cohen’s Revance Therapeutics, Inc. RVNC Stock Holding History

Steven Cohen’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,300
Closed -$286K – 2945
2023
Q2 		$286K Hold
11,300
– – ﹤0.01% 1371
2023
Q1 		$364K Buy
+11,300
New +$352K ﹤0.01% 1316

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

Steven Cohen's RVNC Position: Q3 2024 in Review

Steven Cohen sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 17,100 shares — an estimated $43.9K sold.

Steven Cohen first reported a position in RVNC in Q2 2019 and held it in 12 quarters. The position peaked at $21M in Q3 2021. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Steven Cohen reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Steven Cohen sold 17,100 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $43.9K.
  • Steven Cohen first reported a position in Revance Therapeutics, Inc. in Q2 2019 and held it in 12 quarters.
  • Steven Cohen's Revance Therapeutics, Inc. position peaked at $21M in Q3 2021.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Point72 Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.